Tests a walking app for home gait training in Parkinson's disease
Tests a phone app giving walking cues to people with Parkinson's disease at home.
Plain-language title generated from the registry record
Registry title: Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
Key facts
- Where
- Tel Aviv, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07380737, who can take part
Where in Israel
- Tel Aviv Sourasky Medical Center (Ichilov Hospital)Tel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT07380737
- Record updated
- 13 February 2026
- Original description
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.Read full original descriptionShow less
Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.
Inclusion: Clinical diagnosis of idiopathic Parkinson's disease (MDS criteria); Hoehn \& Yahr stage II-III (ON-medication state); Able to walk independently for ≥5 minutes; Stable medication for ≥1 month; Currently enrolled in a rehab program at Ezra LeMarpe; Able to provide written informed consent.
Exclusion: Participation in other concurrent intervention studies; History of stroke, severe TBI, or brain tumor; Musculoskeletal, neurological, or visual/hearing impairments affecting gait; Cognitive impairments or severe behavioral symptoms; Cardiovascular contraindications; Inability to use a smartphone.